STAT, April 25, 2016. A federal advisory panel voted Monday that a drug from Sarepta Therapeutics was not effective for treating Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease. About 13,000 children, mostly boys, are afflicted.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
To Sway Drug Approval, Patient Advocates Turn up The Heat on the FDA
The Washington Post, April 23, 2016. Parents are desperate for a treatment for their sons with a rare disease, but if FDA approves a drug that isn’t proven to work, we are all at risk. FDA will meet to consider this dilemma on Monday, April 25.
Read More »How the House, Senate Diverge on Patient Safety in Cures Bills
American Health Line, April 19, 2016. Patient safety experts, including Dr. Diana Zuckerman, report that the the Senate’s version of the House-approved 21st Century Cures Act has been updated but still needs more changes.
Read More »Device Recalls Surge in Recent Years, Prompting Question: Why?
General Surgery News, April 12, 2016. The FDA approves or clears thousands of new medical devices each year. This highly complex process of review has garnered criticism in recent years. Dr. Diana Zuckerman weighs in on the lack of quality of clinical testing and the FDA approval process.
Read More »Who’s Calling the Shots in State Politics? Amid Federal Gridlock, Lobbying Rises in the States
The Center for Public Integrity, February 11, 2016. Across America, lobbyists for drugmakers — including Enbrel’s maker Amgen — have worked at a feverish pace to push state laws that make it harder for pharmacists to substitute cheaper biosimilars for brand-name biologic drugs, as is commonly done with regular generic drugs.
Read More »